US LNG exports surge but will buyers in China turn up?
LONDON - Genus plc (LSE: LON:GNS), a global leader in animal genetics, has announced that Professor Jason Chin will retire from his position as a Non-Executive Director at the end of May 2025. Professor Chin, who has contributed four years of service to the company, will be taking on a new role as the Founding Director of the Generative Biology Institute at the Ellison Institute of Technology.
During his tenure, Professor Chin has held roles as the Chairman of Genus’s Scientific Advisory Board and as an advisor to the company’s Global Portfolio Steering Committee. Even after his departure from the Board, he will continue to serve on the Scientific Advisory Board.
Genus’s Chairman, Iain Ferguson, expressed gratitude for Professor Chin’s significant scientific contributions and guidance, which have been instrumental in advancing the company’s science platforms. The Board has commenced a comprehensive search for a successor and will update on the progress in due course.
Genus, headquartered in Basingstoke, United Kingdom (TADAWUL:4280), operates in over 25 countries and conducts research in facilities such as those in Madison, Wisconsin, USA. The company is known for its proprietary animal breeding technologies and services, which it markets under the ’ABS’ and ’PIC’ trademarks for cattle and pigs, respectively. Genus’s products, which include semen, embryos, and breeding animals, are sold in over seventy-five countries. These products aim to enhance production efficiency and quality in livestock, ultimately benefiting the global dairy and meat supply chains.
This announcement, based on a press release statement, is made in accordance with Listing Rule 6.4.6R, with Vaughn Walton, the Interim Company Secretary, responsible for the release of this information.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.